secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K/A
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001140361-23-052753
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q3 net loss $14.0M ($0.24/share); chairman exercises warrants for $10M
--------------------------------------------------------------------------------

- Net loss $14.0M ($0.24 loss per share) vs $8.6M ($0.14) in Q3 2022; includes $3.6M non-cash deemed dividend from warrant modification.
- Chairman Richard Uihlein exercised 2.24M warrants at $4.49/share, providing $10M cash; market price was $1.81.
- Cash and equivalents $20.4M; additional $30M credit line from chairman; cash sufficient through at least Dec 2024.
- Belapectin safety profile positive; interim analysis for NAVIGATE trial expected Q4 2024.
- Dr. Benjamin Carson Sr. nominated to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/ef20014607_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-052753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer